Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin Lymphoma

NCT03238651 is registered in ClinicalTrials.gov with Calithera Biosciences, Inc as lead sponsor.

NCT NCT03238651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03238651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin Lymphoma
Lead sponsor
Calithera Biosciences, Inc
Phase
Phase 1
Overall status
Terminated
Start date
August 1, 2017
Completion date
August 17, 2020
Enrollment
17 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular, marginal zone, lymphoma, non-hodgkin